ECSP993138A - CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL - Google Patents
CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROLInfo
- Publication number
- ECSP993138A ECSP993138A ECSP993138A ECSP993138A EC SP993138 A ECSP993138 A EC SP993138A EC SP993138 A ECSP993138 A EC SP993138A EC SP993138 A ECSP993138 A EC SP993138A
- Authority
- EC
- Ecuador
- Prior art keywords
- drug
- optionally
- pharmaceutical composition
- delivery system
- drug delivery
- Prior art date
Links
- 239000000599 controlled substance Substances 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000002775 capsule Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229960003405 ciprofloxacin Drugs 0.000 abstract 2
- 230000000916 dilatatory effect Effects 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000002123 temporal effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica en forma de tabletas o cápsulas provee una combinación de control temporal y espacial de liberación de una droga a un paciente para resultados terapéuticos efectivos. La composición farmacéutica comprende una droga, un componente generaddor de gas, un agente dilatador, un agwente viscoso, y opcionalmente un polímero formador de gel. El agente dilatador pertenence a un grupo de compuestos conocidos como superdesintegradores (por ejemplo: la polivinilpirrolidona de enlace cruzado o la carboximetilcelulosa de sodio). Inicialmente el agente viscoso y luego el polímero formador de gel, forman una matriz de gel hidratada que ocluye el gas, causando que la tableta o cápsula flten para ser retenidas en el estomago o en la parte alta del intestino delgado (control espacial). Al mismo tiempo la matriz de gel hidratado crea un camino de difusión tortyuoso para la droga, lo que resulta en una liberación sostenida de la droga (control temporal). Una formulación, preferida, de ciprofloxacin administarda una sola vez el dia comprende 69.9% de base de ciprofloxacin 0.34% de alginato de sodio, 1.03% de goma jántica, 13.7% de bicarbonato de sodio, 12.1% de polivinilpirrolidona de enlace cruzado, y opcionalmente otros excipientes farmacéuticos, la formulación está en forma de tabletas recubiertas o no, o en cápsulas.A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug release to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a dilating agent, a viscous solvent, and optionally a gel-forming polymer. The dilating agent belongs to a group of compounds known as super-disintegrators (for example: cross-linked polyvinylpyrrolidone or sodium carboxymethyl cellulose). Initially the viscous agent and then the gel-forming polymer, form a hydrated gel matrix that occludes the gas, causing the tablet or capsule to float to be retained in the stomach or upper part of the small intestine (spatial control). At the same time the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in a sustained release of the drug (temporary control). A preferred formulation of ciprofloxacin administered once a day comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% gum semantics, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally Other pharmaceutical excipients, the formulation is in the form of coated or uncoated tablets, or capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993138 ECSP993138A (en) | 1999-09-14 | 1999-09-14 | CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993138 ECSP993138A (en) | 1999-09-14 | 1999-09-14 | CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993138A true ECSP993138A (en) | 2000-05-08 |
Family
ID=42044126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993138 ECSP993138A (en) | 1999-09-14 | 1999-09-14 | CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993138A (en) |
-
1999
- 1999-09-14 EC ECSP993138 patent/ECSP993138A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5130022A1 (en) | DRUG CONTROLLED DELIVERY SYSTEM ORALALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL | |
| YU19501A (en) | Orally administrated controlled drug delivery system providing temporal and spatial control | |
| ES2267107T3 (en) | FORMULATION OF CONTROLLED RELEASE FOR HYDROSOLUBLE DRUGS IN WHICH ONE STEP IS FORMED IN SITU. | |
| KR100283709B1 (en) | Stable Sustained Release Oral Dosage Composition | |
| RU94032150A (en) | Medicinal agent exhibiting delayed release of active-acting substance | |
| AR004391A1 (en) | CONTROLLED RELEASE FORMULATION FOR BASIC PHARMACS SLIMMY SOLUBLE. | |
| CZ2003199A3 (en) | Quick expanding composition for controlled release of a medicament and retention thereof in stomach and medicinal forms containing such composition | |
| KR20010102088A (en) | Prolonged release bioadhesive vaginal gel dosage form | |
| ATE319431T1 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE AND DELAYED ABSORPTION | |
| HUP9904174A2 (en) | Pharmaceutical composition for transdermic delivery | |
| CN101637462B (en) | Compositions for conjugated estrogens and associated methods | |
| RU2008151949A (en) | PHARMACEUTICAL MEDICINAL FORMS AND Phenylephrine COMPOSITIONS FOR ABSORPTION IN THE COLUMN | |
| DE60038536D1 (en) | MATRIX SYSTEM WITH DELAYED RELEASE FOR HIGHLY SOLUBLE ACTIVE SUBSTANCES | |
| SG146638A1 (en) | Pharmaceutical delivery system | |
| Tiwari et al. | Oral drug delivery system: a review | |
| BR0013719A (en) | Controlled-release oral dosage, suitable for oral administration | |
| SE9301877D0 (en) | IN SITU GEL FOR THERAPEUTIC USE | |
| HN2001000038A (en) | CONTROLLED ORAL ADMINISTRATION SYSTEM FOR DAILY INTAKE OF CIPROFLOXACINE | |
| ES2259011T3 (en) | PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF AN ANTIBIOTIC BETA-LACTAMA. | |
| ECSP993138A (en) | CONTROLLED DRUG DELIVERY SYSTEM ORALLY ADMINISTERED, PROVIDING TEMPORARY AND SPACE CONTROL | |
| NZ703464A (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
| Rajesh et al. | Matrix tablets: A promising tool for oral controlled release drug delivery | |
| ES2330227T3 (en) | PHARMACEUTICAL COMPOSITION OF PROLONGED HYDRALAZINE RELEASE AND ITS USE AS SUPPORT FOR CANCER TREATMENT. | |
| Mahajan et al. | An overview on Superdisintegrants | |
| TH50543A3 (en) | A controlled drug delivery system for oral administration that provides control of time and area. |